Seattle Genetics Price Target Increased to $51.00 by Analysts at Credit Suisse (SGEN)
Research analysts at Credit Suisse upped their target price on shares of Seattle Genetics (NASDAQ:SGEN) from $46.00 to $51.00 in a report released on Thursday, American Banking & Market News reports. Credit Suisse’s target price suggests a potential upside of 0.12% from the stock’s previous close.
A number of other analysts have also recently weighed in on SGEN. Analysts at Guggenheim raised their price target on shares of Seattle Genetics from $33.00 to $38.00 in a research note on Thursday. Separately, analysts at Needham & Company upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, analysts at RBC Capital raised their price target on shares of Seattle Genetics from $44.00 to $48.00 in a research note on Friday, December 20th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $44.24.
Seattle Genetics (NASDAQ:SGEN) opened at 50.49 on Thursday. Seattle Genetics has a 52-week low of $26.60 and a 52-week high of $51.97. The stock has a 50-day moving average of $43.61 and a 200-day moving average of $42.36. The company’s market cap is $6.184 billion.
Seattle Genetics (NASDAQ:SGEN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.24) by $0.11. The company had revenue of $67.40 million for the quarter, compared to the consensus estimate of $59.50 million. During the same quarter last year, the company posted ($0.09) earnings per share. Seattle Genetics’s revenue was up 5.5% compared to the same quarter last year. On average, analysts predict that Seattle Genetics will post $-0.69 earnings per share for the current fiscal year.
Seattle Genetics, Inc is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.